Based on ratings from 13 stock analysts, the Sarepta Therapeutics Inc stock price is expected to increase by 9.13% in 12 months. This is calculated by using the average 12-month stock price forecast for Sarepta Therapeutics Inc. The lowest target is $1.00 and the highest is $224.00. Please note analyst price targets are not guaranteed and could be missed completely.
SRPT is a stock in Health Care which has been forecasted to be worth $139.00 as an average. On the higher end, the forecast price is $224.00 USD by andreas argyrides from Wedbush and on the lower end SRPT is forecasted to be $1.00 by salveen richter from Goldman Sachs.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
uy ear Mizuho Securities | Buy | $130.0 | maintained | Feb 1, 2024 |
tazeen ahmad Bank of America Securities | Buy | $164.0 | maintained | Feb 1, 2024 |
hartaj singh Oppenheimer | Hold | None | maintained | Jan 31, 2024 |
kostas biliouris BMO Capital | Buy | $170.0 | initiatedcoverage | Jan 31, 2024 |
andreas argyrides Wedbush | Buy | $224.0 | rated | Jan 30, 2024 |
joseph schwartz Leerink Partners | Buy | $145.0 | reiterated | Jan 29, 2024 |
brian skorney Robert W. Baird | Buy | $136.0 | maintained | Jan 29, 2024 |
anupam rama J.P. Morgan | Buy | None | reiterated | Jan 29, 2024 |
gil blum Needham | Buy | $140.0 | maintained | Jan 29, 2024 |
david hoang Citi | Buy | $113.0 | maintained | Jan 29, 2024 |
ritu baral TD Cowen | Buy | $135.0 | maintained | Jan 11, 2024 |
salveen richter Goldman Sachs | Buy | $1.0 | reiterated | Jan 8, 2024 |
brian abrahams RBC Capital | Buy | $155.0 | maintained | Jan 3, 2024 |
stephen brozak WBB Securities | Buy | $185.0 | maintained | Dec 29, 2023 |
neena bitritto garg Deutsche Bank | Buy | $109.0 | initiatedcoverage | Dec 11, 2023 |
gena wang Barclays | Buy | $141.0 | maintained | Nov 2, 2023 |
kristen kluska Cantor Fitzgerald | Hold | $40.0 | downgraded | Oct 31, 2023 |
gavin clark gartner Evercore ISI | Hold | $94.0 | maintained | Oct 31, 2023 |
colin bristow UBS | Buy | $174.0 | maintained | Aug 4, 2023 |
judah frommer Credit Suisse | Hold | $139.0 | maintained | Aug 3, 2023 |
In 2023, SRPT generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that SRPT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
SPLK-USD
$154.42
TEAM-USD
$216.17
TXN-USD
$162.4
UPST-USD
$33.9
TXG-USD
$49.11
TWKS-USD
$4.41